Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.3.1 (alkaline phosphatase)
 47,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Twelve patients with disseminated breast cancer were injected with monoclonal antibody MBr1 at the National Cancer Institute of Milan, Italy, from January 1983 to March 1985. The first seven patients had advanced disease and the remaining five operable breast cancer. In the first seven patients the initial dosage of MBr1 was 0.5 mg and was doubled in the next patient up to 16 mg. The last five women received 10 mg of MBr1. No general side effects such as bronchospasm, hypotension, immediate or delayed allergic reactions were observed. Four patients who were injected with 10 mg or more experienced fever, shudder and vague abdominal and articular pain. The following tests were monitored: R.B.C., W.B.C., percentage of lymphocytes, blood glucose, urea nitrogen and creatinine, serum levels of Na+, K+, Cl-, total proteins levels, albumins and globulins, bilirubin, GOT, GPT, alkaline phosphatase, LDH, amylase, gamma GT and CPK. No major modifications were observed: a limited increase of the transaminases, LDH and gamma GT was evident at the last check. An early temporary alteration of CPK was observed in the four patients who had symptoms. Serum levels of MBr1 are detectable immediately after injection starting from 4 mg, and all sera were negative 48 hours later. It is concluded that the scanty toxicity allows to continue clinical investigations to verify the linkage between MBr1 and Ca-MBr1 "in vivo" after a single injection of no more than 16 mg of the MoAb. The increase of this dosage as well as multiple injections do not seem safe at present.
 ...
PMID:Evaluation of toxic effects following administration of monoclonal antibody MBr1 in patients with breast cancer. 287 47

The cases of a 43 years old-man with gout and a 24 years-old woman with severe back pain who developed dextro-propoxyphene addiction during pain treatment are reported. They had severe edema and fibrosis of skin, subcutaneous tissue and muscle involving the upper and lower limbs. ESR was elevated, CPK and LDH were normal. EMG in proximal muscles showed decreased duration and voltage of potentials, excess of short polyphasics and increased recruitment (BSAP), with positive waves and fibrillations; distal muscles had fasciculations, fibrillations, positive waves, normal voluntary potentials, decreased recruitment. Lymphography indicate delayed progression of contrast media and obstruction in the thighs. Muscle biopsy on fresh-frozen section and histochemistry showed extensive connective tissue proliferation with intense acid and alkaline phosphatase activity in the perimysial and endomysial area, infiltration of lymphocytes near and around small vessels and capillaries. There were perifascicular and type II fiber atrophy. After discharge the patients returned to propoxyphene addiction and the symptoms who subsided during drug withdrawal come back again. New admission, new drug withdrawal and they were discharged free of symptoms and pathologic changes.
 ...
PMID:[Myopathy caused by propoxyphene: report of 2 cases with muscle histochemistry]. 616 47

Serum enzymes and articular radionuclide tests have a restricted application in solving the current diagnostic and differential-diagnostic problems of present-day rheumatology. The enzyme tests became positive in case of a high activity of rheumatoid arthritis, not objectivizing the articular degeneration. Their correlation with radionuclide tests of the patients with osteoarthrosis and the patients with rheumatoid arthritis is not elucidated. A juxtaposition was made of the serum enzymes with the articular radionuclide quantitative indices in 88 patients with rheumatoid arthritis with various clinical-laboratory activity, 88 patients with osteoarthrosis in various X-ray stages and 22 healthy controls. A correlation dependence was established between LDH, CPK, acid phosphatase, clearance effectiveness of articular cavity and the deposition of 99mTc-pyrophosphate in knee joints of the patients with osteoarthritis and between gamm-GT, alkaline phosphatase, acid phosphatase and radionuclide articular indices of the patients with rheumatoid arthritis. Those characteristics enabled the earlier overcoming of the diagnostic difficulties in those two basic rheumatic diseases.
 ...
PMID:[Relation between serum enzymes and articular radionuclide tests in the diagnosis of osteoarthrosis and rheumatoid arthritis]. 626 61

Amine-curing agent for epoxy resin, bis(4-amino-3-methylcyclohexyl)methane, has been suspected of inducing toxic symptoms in man which resemble collagen disease such as scleroderma or polymyositis. We studied subacute toxicity of this agent by repeated oral administrations to rats. The agent was administered 25, 37.5, 50, 75 or 100 mg/kg per one dose, 8 times in 10 days or 17 times in 4 weeks or 20-22 times in 4 weeks. When administration had been completed, clinical biochemical tests and histopathological examinations were carried out. Animals of high dosage group showed suppression of body weight increase and loss of muscular strength of limbs in the administration period. By clinical biochemical tests, elevation of blood components from muscle (CPK, GOT, creatine) was noticed. Also, increase of monoamine oxidase and decrease of alkaline phosphatase were revealed. By histological examinations, skeletal muscle and choroid plexus of brain showed noticeable changes. In muscles of high dosage group, atrophy, degeneration and regeneration of muscle fibers were observed and an increase of fibroblasts was also seen. In choroid plexus, vacuolar changes in epithelial cells were observed, being clearly dose-dependent. No particular change was recognized in skin. Though scleroderma-like change was not observed in the skin histologically, our results suggest that this amine-curing agent was greatly associated with muscle symptoms in the workers who handled epoxy resin and that it was one of causative agents which induced toxic symptoms like those of collagen disease.
 ...
PMID:[Subacute toxicity of an amine-curing agent for epoxy resin]. 652 Oct 56

Twenty mares were assigned to 1 of 4 groups: no altrenogest; altrenogest at 0.044 mg/kg BW; altrenogest at 0.132 mg/kg BW; or altrenogest at 0.220 mg/kg BW. Treatment was administered daily for 86 days. No signs of illness attributable to feeding altrenogest were observed during the trial. Treatment had no effect (P greater than .05) on the following parameters: WBC, differential WBC, platelet number, creatinine, LDH, CPK, total bilirubin, cholesterol, globulin, BSP, and erythrocyte sedimentation rate. When comparing values over time with pretreatment means or among treatment groups, there were differences (P less than .05) in RBC, PCV, Hb, ALT, PT, PTT, P, Na, TP, BUN, Cl and glucose. However, these changes remained within established normal ranges and also occurred in mares in the control group. There was no treatment by time interaction for any of these parameters. Treatment differences (P less than .05) were observed for K, Ca, alkaline phosphatase and AST during the course of the trial. However, only occasional values of these parameters were outside the established ranges. They were only slightly elevated and tended to be either sporadic or also occurred in control mares. Few of the observed changes could be attributed to the feeding of altrenogest.
 ...
PMID:The effect of altrenogest, an oral progestin, on hematologic and biochemical parameters in mares. 668 30

The lipid-reducing effects of bezafibrate and clofibrate were investigated in a double-blind crossover trial. 3 x 200 mg/d bezafibrate and 3 x 500 mg/d clofibrate were administered for periods of 8 weeks each to 22 patients with primary hyperlipoproteinaemia (9 Type IIb, 13 Type IV). Placebo periods preceded and followed the periods of medication. Compliance was checked by determination of the serum concentrations of bezafibrate and clofibrate. As compared with the pre-therapy value under placebo, cholesterol was reduced by 14% with bezafibrate and 7% with clofibrate in the group as a whole. In Type IIb patients cholesterol was reduced by 16% with bezafibrate as against 10% with clofibrate, and in Type IV patients by 12% with bezafibrate and 6% with clofibrate. A similar response was found in triglyceride reduction: 36% vs. 18% for the group as a whole; 47% vs. 31% for Type IIb; and 29% vs. 9% for Type IV. The difference in triglyceride reduction for the group as a whole was significant at the p less than 0.05 level. Body weight, pulse rate, and blood pressure showed no changes during the entire period of investigation. Fasting blood glucose was somewhat lower under both substances than under the subsequent placebo period while urea-N and creatinine was increased for both as compared with both pre- and post-therapy placebo periods. Under bezafibrate there was an increase in CPK as compared with the second placebo phase. There were no changes in GOT and GPT. Reductions in gamma-GT, alkaline phosphatase, and bilirubin were observed under both bezafibrate and clofibrate, as were slight decreases in haemoglobin, erythrocytes, and leucocytes, and a small increase in thrombocytes. No changes in urinary excretion of protein or glucose were observed. No subjective side effects were reported, either for bezafibrate or for clofibrate.
 ...
PMID:[Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia]. 698 60

Three Shetland ponies were given a single oral dose of ground Cassia occidentalis seeds in aqueous suspension. The clinical signs observed resembled those seen in naturally occurring and experimental cases in cattle. The syndrome was characterized by an afebrile course, incoordination, recumbency and death. Elevations of blood alkaline phosphatase, CPK, LDH, and SGOT were observed. Although muscle lesions were not seen grossly, microscopic lesions included segmental necrosis of skeletal muscle fibers. The findings were regarded as sufficiently characteristic of C. occidentalis poisoning to be useful in differential diagnosis. When Cassia poisoning is suspected, access of the affected horses to the plant should be demonstrated.
 ...
PMID:Toxicity of Cassia occidentalis in the horse. 733 63

Diurnal variations in 23 blood chemical items were investigated in Sprague-Dawley rats of both sexes at 6 weeks of age. Blood samples were obtained every two hours. One to three periodic components detected by the maximum entropy method from the observed time-series and the optimum fitting parameters were calculated by the least squares method. The fitting curves were compared with the observed data for the evaluation of systematic and fluctuating parts of the time domain as circadian variations. The periodic components were detected from all the blood chemical items examined. This suggests that all items have systematic parts as basic rhythmic changes. The optimum fitting curves corresponded to the observed time-series in the following items: glucose, total protein, A/G ratio, alkaline phosphatase, Na, K, Cl and BUN of both sexes and total cholesterol, triglyceride, cholinesterase, CPK, inorganic phosphorus, direct and total bilirubin, creatinine and uric acid in males. Others showed insufficient correspondence to many fluctuating parts. This randomness was more frequently seen in females than in males.
 ...
PMID:Diurnal variations in blood chemical items in Sprague-Dawley rats. 755 24

The efficacy and safety of acipimox, an antilipolytic agent, were studied in 10 uremic patients under hemodialysis (group A) and in 8 renal transplant recipients with adequate renal function (group B). The medication was given for 20 weeks at a dose of 250 mg daily in both groups. Total serum cholesterol decreased significantly from 218.1 +/- 17.4 to 175.2 +/- 15.2 mg/dL (-19.7%) in group A and from 261.2 +/- 16.5 to 215.3 +/- 26.9 mg/dL (-17.6%) in group B; as did serum triglycerides, from 206.7 +/- 26.9 to 146.9 +/- 17.6 mg/dL (-29%) in group A and from 168.2 +/- 20.6 to 111.3 +/- 12.4 mg/dL (-33.8%) in group B. Low-density lipoprotein (LDL)-cholesterol and very low-density lipoprotein (VLDL)-cholesterol were also decreased significantly (LDL-C by -27% and -25%, and VLDL-C by -29.2% and -33.8% in groups A and B, respectively). Furthermore, the high-density lipoprotein (HDL)-cholesterol was increased significantly, by +29.6% in group A and +18% in group B. The apolipoproteins Apo-A1 and Apo-A2 were decreased in Group A but not in group B. The Apo-B was decreased in group B. Serum CPK (total and muscle fraction), total bilirubin, SGPT, SGOT, alkaline phosphatase, gamma GT, LDL, a-Fp, and creatinine remained unchanged in both groups. Acipimox seems to be effective in the regulation of atherogenic lipid disorders in hemodialysis patients and renal transplant recipients, without any muscular damage or alteration of kidney and liver function.
 ...
PMID:Lipid-lowering effect and safety of acipimox in hemodialysis patients and renal transplant recipients. 805 22

The results of an external quality assessment scheme (EQAS), carried out in the Latium region between October 1987 and December 1988, are reported. Ninety-four laboratories, both public and private, took part in the scheme. Aim of the scheme was to estimate the reliability of the clinical chemistry services in this region. The participating laboratories received eight control samples for EQA, every two months. The analytes to be determined in each sample were: glucose (GLU), urea (UR), total protein (TP), uric acid (UA), creatinine (CR), bilirubin (BIL), cholesterol (CHO), triglycerides (TRI), sodium (Na), potassium (K), calcium (Ca), aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CPK), gamma glutamyl transferase (GGT), and alkaline phosphatase (ALP). Global laboratory performances were evaluated in terms of interlaboratory precision, accuracy--as deviation per cent from the target values and coefficient of variation (CV)--and percentage of results within pre-set acceptability limits. The deviations were reasonably low, whereas the CVs were rather high. The percentage of acceptable results was lower than 50% for the analytes urea, calcium, uric acid, creatine kinase and alkaline phosphatase. The performance of the examined laboratories was worse than those obtained in other regional and national EQAS, both in terms of CVs and percentage of acceptable results.
 ...
PMID:Organization and results of a pilot scheme for external quality assessment in clinical chemistry carried out in the Latium region, Italy. 854 59


<< Previous 1 2 3 Next >>